Company intelligence / Profile preview

Animab

Zwijnaarde, Belgium

Ownership: Private
Development stage: Other

Overview

Nanoprotec demonstrated significant reduction in ETEC F4-related symptoms in clinical trials. Regulatory filing to EMA planned by end of 2025 with market launch expected by end of 2026.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyOral antibody
Industry: Veterinary

Partnerships

Huvepharma (exclusive distribution agreement)

Beyond the preview

Go deeper on Animab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Animab.

Explore the full profile